ICON Public Limited Company (ICLR) Forms $121.22 Double Top; Geron Has 0.93 Sentiment

Geron Corporation (NASDAQ:GERN) Logo

ICON Public Limited Company (ICLR) formed double top with $130.92 target or 8.00% above today’s $121.22 share price. ICON Public Limited Company (ICLR) has $6.56B valuation. The stock increased 0.31% or $0.38 during the last trading session, reaching $121.22. About 187,184 shares traded. ICON Public Limited Company (NASDAQ:ICLR) has risen 52.69% since April 19, 2017 and is uptrending. It has outperformed by 41.14% the S&P500.

Geron Corp (GERN) investors sentiment decreased to 0.93 in Q4 2017. It’s down -0.04, from 0.97 in 2017Q3. The ratio is negative, as 38 hedge funds opened new or increased positions, while 41 sold and decreased holdings in Geron Corp. The hedge funds in our database now own: 58.72 million shares, down from 61.75 million shares in 2017Q3. Also, the number of hedge funds holding Geron Corp in top ten positions was flat from 0 to 0 for the same number . Sold All: 11 Reduced: 30 Increased: 25 New Position: 13.

Analysts await Geron Corporation (NASDAQ:GERN) to report earnings on May, 8. They expect $-0.04 earnings per share, up 20.00% or $0.01 from last year’s $-0.05 per share. After $-0.05 actual earnings per share reported by Geron Corporation for the previous quarter, Wall Street now forecasts -20.00% EPS growth.

Nj State Employees Deferred Compensation Plan holds 0.09% of its portfolio in Geron Corporation for 280,000 shares. Fernwood Investment Management Llc owns 16,000 shares or 0.02% of their US portfolio. Moreover, A.R.T. Advisors Llc has 0.01% invested in the company for 85,300 shares. The New Jersey-based Brave Asset Management Inc has invested 0.01% in the stock. Family Management Corp, a New York-based fund reported 10,200 shares.

Geron Corporation operates as a biopharmaceutical company. The company has market cap of $600.85 million. The firm supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It currently has negative earnings. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

The stock decreased 6.27% or $0.25 during the last trading session, reaching $3.74. About 4.69 million shares traded. Geron Corporation (GERN) has risen 126.87% since April 19, 2017 and is uptrending. It has outperformed by 115.32% the S&P500.

Among 12 analysts covering Icon plc (NASDAQ:ICLR), 7 have Buy rating, 1 Sell and 4 Hold. Therefore 58% are positive. Icon plc has $145.0 highest and $77 lowest target. $120.55’s average target is -0.55% below currents $121.22 stock price. Icon plc had 40 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, July 27 by Jefferies. On Friday, December 16 the stock rating was downgraded by SunTrust to “Hold”. Goldman Sachs upgraded the shares of ICLR in report on Friday, December 16 to “Buy” rating. The rating was maintained by Jefferies on Tuesday, January 9 with “Buy”. The stock of ICON Public Limited Company (NASDAQ:ICLR) has “Outperform” rating given on Tuesday, June 21 by Credit Suisse. The stock of ICON Public Limited Company (NASDAQ:ICLR) earned “Buy” rating by SunTrust on Monday, July 31. KeyBanc Capital Markets maintained the shares of ICLR in report on Monday, November 13 with “Buy” rating. The stock of ICON Public Limited Company (NASDAQ:ICLR) earned “In-Line” rating by Evercore on Tuesday, April 3. On Monday, October 16 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. The rating was upgraded by Evercore to “Buy” on Friday, October 14.

Analysts await ICON Public Limited Company (NASDAQ:ICLR) to report earnings on May, 3 before the open. They expect $1.41 EPS, up 9.30% or $0.12 from last year’s $1.29 per share. ICLR’s profit will be $76.26 million for 21.49 P/E if the $1.41 EPS becomes a reality. After $1.43 actual EPS reported by ICON Public Limited Company for the previous quarter, Wall Street now forecasts -1.40% negative EPS growth.

Geron Corporation (NASDAQ:GERN) Institutional Positions Chart